会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明公开
    • 메트립타아제-특이적인 인간 항체 및 그의 용도
    • 基因特异性全身人体抗体及其用途
    • KR1020130091132A
    • 2013-08-16
    • KR1020120012429
    • 2012-02-07
    • 한국생명공학연구원한국전자통신연구원
    • 박영우김동진박지현손명호이기세이유라성건용김완중박찬우아칠성양종헌정광효최요한장명희
    • C07K16/18C12N15/13A61K39/395A61P35/00
    • PURPOSE: Metriptase-specific human antibody is provided to be usefully used to diagnosis, prevention and treatment of cancer which is a disease related to the manifestation and be especially used as a kit for cancer diagnosis. CONSTITUTION: Human monoclonal antibody specific to matriptase protein or a fraction having immunological activity of the antibody comprises heavy chain complementarity determining regions (HCDR1) having an amino acid sequence of the sequence number 12, heavy chain that includes the heavy variable domain (V_H) which includes HCDR2 having an amino acid sequence of the sequence number 13 and HCDR3 having an amino acid sequence of the sequence number 14, light chain complementarity determining regions (HCDR1) having an amino acid sequence of the sequence number 16 and light chain having light variable domain (V_L) which includes LCDR2 having an amino acid sequence of the sequence number 17 and LCDR3 having an amino acid sequence of the sequence number 18.
    • 目的:提供Metriptase特异性人抗体用于诊断,预防和治疗癌症,这是一种与表现相关的疾病,特别用作癌症诊断的试剂盒。 构成:具有对matriptase蛋白质或具有抗体免疫活性的级分的人单克隆抗体包括具有序列号12的氨基酸序列的重链互补决定区(HCDR1),重链包括重链可变结构域(V_H),重链可变区 包括具有序列号13的氨基酸序列的HCDR2和具有序列号14的氨基酸序列的HCDR3,具有序列号16的氨基酸序列的轻链互补决定区(HCDR1)和具有光可变结构域的轻链 (V_L),其包括具有序列号17的氨基酸序列的LCDR2和具有序列号18的氨基酸序列的LCDR3。